Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment

Xu, Rui; Yang, Tao; Yan, Bing; You, Junhao; Li, Fang; Zuo, Qiang

doi:10.3892/ol.2023.13855

Cited by 2 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…( 49 ) indicated that elevated pretreatment plasma fibrinogen levels are significantly associated with reduced survival rates in patients with solid tumors. In immunotherapy, initial fibrinogen concentrations correlate with patient prognoses ( 50 ). Further research has underscored fibrinogen’s involvement in cell migration, proliferation, angiogenesis, and hematogenous metastasis ( 51 , 52 ).…”

Section: Discussionmentioning

confidence: 99%

Pulmonary function test-related prognostic models in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy

Zhang,

Zhu,

Liang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThis study aimed to establish a comprehensive clinical prognostic risk model based on pulmonary function tests. This model was intended to guide the evaluation and predictive management of patients with resectable stage I-III non-small cell lung cancer (NSCLC) receiving neoadjuvant chemoimmunotherapy.MethodsClinical pathological characteristics and prognostic survival data for 175 patients were collected. Univariate and multivariate Cox regression analyses, and least absolute shrinkage and selection operator (LASSO) regression analysis were employed to identify variables and construct corresponding models. These variables were integrated to develop a ridge regression model. The models’ discrimination and calibration were evaluated, and the optimal model was chosen following internal validation. Comparative analyses between the risk scores or groups of the optimal model and clinical factors were conducted to explore the potential clinical application value.ResultsUnivariate regression analysis identified smoking, complete pathologic response (CPR), and major pathologic response (MPR) as protective factors. Conversely, T staging, D-dimer/white blood cell ratio (DWBCR), D-dimer/fibrinogen ratio (DFR), and D-dimer/minute ventilation volume actual ratio (DMVAR) emerged as risk factors. Evaluation of the models confirmed their capability to accurately predict patient prognosis, exhibiting ideal discrimination and calibration, with the ridge regression model being optimal. Survival analysis demonstrated that the disease-free survival (DFS) in the high-risk group (HRG) was significantly shorter than in the low-risk group (LRG) (P=2.57×10-13). The time-dependent receiver operating characteristic (ROC) curve indicated that the area under the curve (AUC) values at 1 year, 2 years, and 3 years were 0.74, 0.81, and 0.79, respectively. Clinical correlation analysis revealed that men with lung squamous cell carcinoma or comorbid chronic obstructive pulmonary disease (COPD) were predominantly in the LRG, suggesting a better prognosis and potentially identifying a beneficiary population for this treatment combination.ConclusionThe prognostic model developed in this study effectively predicts the prognosis of patients with NSCLC receiving neoadjuvant chemoimmunotherapy. It offers valuable predictive insights for clinicians, aiding in developing treatment plans and monitoring disease progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Pulmonary function test-related prognostic models in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy

Zhang,

Zhu,

Liang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Haemostatic Proteins as Markers of Disease Progression and Prognosis in Breast Cancer

Izuegbuna

2024

Preprint

View full text Add to dashboard Cite

BACKGROUND: Breast cancer is a leading cause of cancer death in women worldwide. One of the major causes of death from breast cancer is metastatic disease which results from the malignant cells invading and migrating through blood vessels to distant sites. TEXT: Several studies have shown that metastasis is facilitated by haemostatic proteins. Breast cancer is characterized by haemostatic imbalance which is tilted more to a procoagulant state with resultant thrombotic complications. These elements that are involved in thrombosis also play key roles in different aspects of breast cancer growth including cancer proliferation and progression, cancer survival, angiogenesis and metastasis. Some of these elements include platelets, endothelial cells, coagulation factors and fibrinolytic proteins. There is a close relationship between cancer and many of the haemostatic elements. They are usually increased in metastatic breast cancer, and have found use as predictive and prognostic markers. Some have been validated in breast cancer. Due to their seemingly active roles in breast cancer progression, some of the haemostatic proteins are being developed as diagnostic tools in the management of breast cancer. They are equally being seen as potential targets for the development of novel therapies in breast cancer or repurposing drugs in current use for the same gain. CONCLUSION: This review highlights the role haemostatic proteins play in breast cancer progression, and their diagnostic and therapeutic relevance.

show abstract

Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment

Cited by 2 publications

References 52 publications

Pulmonary function test-related prognostic models in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy

Pulmonary function test-related prognostic models in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy

Haemostatic Proteins as Markers of Disease Progression and Prognosis in Breast Cancer

Contact Info

Product

Resources

About